DSDrishty Satpati

Drishty Satpati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Drishty Satpati has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cationic amino acid-engineered radiopeptides for breast cancer targeting

    by Akanksha Jain, Manoj Kumar, R. Vasumathy, Amit Das, Ananda Majumdar Guha, Apeksha Khare, Drishty Satpati

  • Open Access

    Influence of Peptide‐Based Chelator Sequences on HER2‐Targeting Radiopeptide

    by Sonal Gupta, Manoj Kumar, Krishna Mohan Repaka, Amit Das, Ajit A. Kengar, Drishty Satpati

    In our pursuit of developing HER2‐targeting radiolabeled peptides for detection and therapy of HER2‐positive breast cancer, the previously reported rL‐A9 peptide had shown promising potential. In the present work, a different variant of rL‐A9 was designed by incorporation of peptide‐based chelators for 99m Tc‐labeling. Cysteine‐based amino acids (CGGG, CSSG, CEEG) were conjugated at the N‐terminus of the peptide and were radiolabeled with [ 99m Tc]NaTcO 4 . Of the three radiopeptides, [ 99m Tc]Tc‐CGGG‐rL‐A9 exhibited high stability, whereas [ 99m Tc]Tc‐CSSG‐rL‐A9 and [ 99m Tc]Tc‐CEEG‐rL‐A9 decomposed rapidly. Hence, only CGGG‐incorporated radiopeptide was further investigated in vitro in human breast carcinoma SKBR3 cells and in vivo in tumor xenografted mice. Cell‐binding studies demonstrated high binding affinity [K d : 5.82 ± 0.92 nM] and specificity (63% reduction in blocking study) of [ 99m Tc]Tc‐CGGG‐rL‐A9 toward HER2‐expressing cells. In vivo studies showed moderate tumor uptake (3.56 ± 0.81% ID/g, 1 h) with 82.8% retention at 3 h (3.16 ± 0.22% ID/g). Moderately high tumor‐to‐background ratios, along with washout from the other non‐target organs, were observed. Inhibition studies revealed 52.6% reduction in the tumor activity, signifying high HER2‐receptor specificity of the presently studied radiopeptide, [ 99m Tc]Tc‐CGGG‐rL‐A9.

  • Cancer Targeting Radiopeptidomimetics in Molecular Nuclear Medicine

    by Drishty Satpati

    Peptides are highly receptor-affine molecules exhibiting suitable pharmacokinetics. Additionally, low-cost production, simple protocols allowing easy modifications, and tolerance toward harsh reaction conditions make peptides ideal ligands for preparation of radiopharmaceuticals for cancer detection and treatment. However, natural peptides being substrates for enzymes are susceptible to proteolysis, which limits the in vivo lifetime and the target uptake. Therefore, the majority of peptides are not able to progress beyond preclinical research. Advancement of peptides for clinical analysis needs modification to instill improved features. Continuous increase and further expected rise in cancer cases in the next decade require development of more disease-directed and promising radiopharmaceuticals. Redesigned peptide, mimicking the original peptide with similar or improved affinity and high metabolic stability, shall have significant edge. This review outlines the design of peptidomimetics by incorporation of D-amino acids (inverso); reversal of D-amino acid sequence (retro-inverso), and reversal of L-amino acid sequence (retro). Clinically successful radiopeptidomimetics prepared using the three approaches have been elaborated to elucidate the important role of peptidomimetics in cancer management.


  • 99mTc‐HYNIC PEGylated Peptide Probe Targeting HER2‐Expression in Breast Cancer

    by Sushree Arpitabala Yadav, V. Kusum Vats, Sonal Gupta, Krishna Mohan Repaka, Drishty Satpati

    Increased HER2 expression during breast cancer and its metastatic spread can be checked by specific probes having high affinity towards the target. This study aimed at developing 99mTc‐labelled HER2‐specific molecular probe for accurate detection. The two rL‐A9 peptide variants, HYNIC‐rL‐A9 and HYNIC‐PEG12‐rL‐A9 were manually synthesized by solid phase methodology. 99mTc‐labelling of peptides was accomplished using EDDA and tricine as co‐ligands. [99mTc]Tc‐HYNIC‐rL‐A9 showed poor uptake in HER2‐expressing human breast carcinoma SKBR3 cells whereas the PEGylated counterpart [99mTc]Tc‐HYNIC‐PEG12‐rL‐A9 demonstrated high specific cellular uptake (3.01% ± 0.14%) and low nanomolar binding affinity (Kd = 17.11 ± 7.63 nM). Tumour uptake (SKBR3) of [99mTc]Tc‐HYNIC‐PEG12‐rL‐A9 was higher at 1 and 3 h in comparison to the non‐PEGylated radiopeptide. Blocking studies led to 70% reduction in accumulation of radioactivity in the tumour indicating specificity of the radiopeptide. Introduction of polyethylene glycol (PEG12) as pharmacokinetic modifier led to significantly improved biological profile of the [99mTc]Tc‐HYNIC‐labelled rL‐A9 peptide conjugate.


  • Influence of PEGylation on HER2-targeting retro A9 peptide analogue

    by Sushree Arpitabala Yadav, V. Kusum Vats, Rohit Sharma, Archana Mukherjee, Drishty Satpati


  • 177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide

    by Sushree Arpitabala Yadav, V. Kusum Vats, Rohit Sharma, Nitish Chauhan, Mahesh Subramanian, Amit Das, Drishty Satpati

  • Peptide‐drug conjugate designated for targeted delivery to HER2‐expressing cancer cells

    by Amit Kumar Sharma, Rohit Sharma, Nitish Chauhan, Amit Das, Drishty Satpati

    Targeted therapy of the highest globally incident breast cancer shall resolve the issue of off‐target toxicity concurring with augmented killing of specific diseased cells. Thus, the goal of this study was to prepare a peptide‐drug conjugate targeting elevated expression of HER2 receptors in breast cancer. Towards this, the rL‐A9 peptide was conjugated with the chemotherapeutic drug doxorubicin (DOX) through a N‐succinimidyl‐4‐(N‐maleimidomethyl) cyclohexane‐1‐carboxylate (SMCC) linker. The synthesized peptide‐drug conjugate, rL‐A9‐DOX, was characterized by mass spectrometry. Molecular docking studies, based on binding energy data, suggested a stronger interaction of rL‐A9‐DOX with the HER2 receptor in comparison to the unconjugated peptide, rL‐A9. The cytotoxic effect of the rL‐A9‐DOX conjugate was observed to be higher in HER2‐positive SKOV3 cells compared to HER2‐negative MDA‐MB‐231 cells, indicating selective cell killing. Cellular internalization of the rL‐A9‐DOX conjugate was evident from the flow cytometry analysis, where a noticeable shift in mean fluorescent intensity (MFI) was observed for the conjugate compared to the control group. This data was further validated by confocal microscopy, where the fluorescent signal ascertained nuclear accumulation of rL‐A9‐DOX. The present studies highlight the promising potential of rL‐A9‐DOX for targeted delivery of the drug into a defined group of cancer cells.


  • Nuclear Localization Signal Enhances the Targeting and Therapeutic Efficacy of a Porphyrin-Based Molecular Cargo: A Systemic In Vitro and Ex Vivo Evaluation

    by Naveen Kumar, Amit K. Sharma, Mohini Guleria, Sandeep B. Shelar, Avik Chakraborty, Sutapa Rakshit, Soumi Kolay, Drishty Satpati, Tapas Das

    The objective of the present work was to evaluate the potential of a nuclear localization signal (NLS) toward facilitating intracellular delivery and enhancement in the therapeutic efficacy of the molecular cargo. Toward this, an in-house synthesized porphyrin derivative, namely, 5-carboxymethyelene-oxyphenyl-10,15,20-tris(4-methoxyphenyl) porphyrin (UTriMA), was utilized for conjugation with the NLS sequence [PKKKRKV]. The three compounds synthesized during the course of the present work, namely DOTA-Lys-NLS, DOTA-UTriMA-Lys-NLS, and DOTA-Lys-UTriMA, were evaluated for cellular toxicity in cancer cell lines (HT1080), wherein all exhibited minimal dark toxicity. However, during photocytotoxicity studies with DOTA-Lys-UTriMA and DOTA-UTriMA-Lys-NLS conjugates in the same cell line, the latter exhibited significantly higher light-dependent toxicity compared to the former. Furthermore, the photocytotoxicity for DOTA-UTriMA-Lys-NLS in a healthy cell line (WI26VA4) was found to be significantly lower than that observed in the cancer cells. Fluorescence cell imaging studies carried out in HT1080 cancer cells revealed intracellular accumulation for the NLS-conjugated porphyrin (DOTA-UTriMA-Lys-NLS), whereas unconjugated porphyrin (DOTA-Lys-UTriMA) failed to do so. To evaluate the radiotherapeutic effects of the synthesized conjugates, all three compounds were radiolabeled with Lu-177, a well-known therapeutic radionuclide with high radiochemical purity (>95%). During in vitro studies, the [Lu-177]Lu-DOTA-UTriMA-Lys-NLS complex exhibited the highest cell binding as well as internalization among the three radiolabeled complexes. Biological distribution studies for the radiolabeled compounds were performed in a fibrosarcoma-bearing small animal model, wherein significantly higher accumulation and prolonged retention of [Lu-177]Lu-DOTA-UTriMA-Lys-NLS (9.32 +/- 1.27% IA/g at 24 h p.i.) in the tumorous lesion compared to [Lu-177]Lu-UTriMA-Lys-DOTA (2.3 +/- 0.13% IA/g at 24 h p.i.) and [Lu-177]Lu-DOTA-Lys-NLS complexes (0.26 +/- 0.17% IA/g at 24 h p.i.) were observed. The results of the biodistribution studies were further corroborated by recording serial SPECT-CT images of fibrosarcoma-bearing Swiss mice administered with [Lu-177]Lu-DOTA-UTriMA-Lys-NLS at different time points. Tumor regression studies performed with [Lu-177]Lu-DOTA-UTriMA-Lys-NLS in the same animal model with two different doses [250 mu Ci (9.25 MBq) and 500 mu Ci (18.5 MBq)] resulted in a significant reduction in tumor mass in the treated group of animals. The above results revealed a definite enhancement in the targeting ability of molecular cargo upon conjugation with NLS and hence indicated that this strategy may be helpful for the preparation of drug-NLS conjugates as multimodal agents.


  • Design, synthesis and evaluation of 177Lu-labeled inverso and retro-inverso A9 peptide variants targeting HER2-overexpression

    by Amit Kumar Sharma, Rohit Sharma, Haladhar Dev Sarma, Archana Mukherjee, Tapas Das, Drishty Satpati


  • Synthesis and 177Lu Labeling of the First Retro Analog of the HER2-Targeting A9 Peptide: A Superior Variant

    by Amit Kumar Sharma, Rohit Sharma, Amit Das, Avik Chakraborty, Sutapa Rakshit, Haladhar Dev Sarma, Archana Mukherjee, Tapas Das, Drishty Satpati

    The retro analog of the HER2-targeting A9 peptide was synthesized by coupling amino acids in a reverse fashion and switching the N-terminal in the original sequence of the L-A9 peptide (QDVNTAVAW) to the C-terminal in rL-A9 (WAVATNVDQ). Modification in the backbone resulted in higher conformational stability of the retro peptide as evident from CD spectra. Molecular docking analysis revealed a higher HER2 binding affinity of [177Lu]Lu-DOTA-rL-A9 than the original radiopeptide [177Lu]Lu-DOTA-L-A9. Enormously enhanced metabolic stability of the retro analog led to significant elevation in tumor uptake and retention. SPECT imaging studies corroborated biodistribution results demonstrating a remarkably higher tumor signal for [177Lu]Lu-DOTA-rL-A9. The presently studied retro probe has promising efficiency for clinical screening.